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INTRODUCTION
The thromboembolic phenomena relating to the post-
operative period following orthopedic surgery are well 
known and greatly studied. They represent high medi-
cal and hospital costs. For decades, medications with 
the capacity to reduce the risk of deep vein thrombosis 
(DVT) and its main complication, pulmonary throm-
boembolism (PTE), have been studied(1).
A variety of drugs are used with the aim of preventing 
and treating these phenomena. Among these are prepara-
tions using non-fractionated heparin and low molecular 
weight heparin, such as enoxaparin, cumarinic agents 
and new medications that are selective inhibitors of fac-
tor Xa(2).
Comparing these different drugs with each other, 
their efficacy for anticoagulation and safety in relation 
to the risk of hemorrhage has been well established in 
the medical literature(3-6). However, their safety in rela-
tion to changes in liver function is not well known(7-8).
The aim of the present study was to evaluate changes 
in liver function among patients undergoing total hip 
arthroplasty with the use of enoxaparin.
ABSTRACT
Objective: To evaluate hepatic changes resulting from the use 
of enoxaparin for prophylaxis of deep vein thrombosis among 
patients undergoing total hip arthroplasty. Methods: Thirty-two 
patients underwent elective total hip arthroplasty, using enox-
aparin, and were followed up for 65 days with serial hepatic 
enzyme assays. Results: Changes in laboratory parameters were 
found in up to 75% of the patients during the study, but the pa-
rameters normalized after suspension of the treatment. No clini-
cal evidence of hepatic lesions was found. Conclusion: The he-
patic enzyme levels increase in most patients using enoxaparin, 
but without clinical correlation, and the levels normalize after 
suspension of the treatment.
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METHODS
Thirty-two patients who were candidates for total hip 
arthroplasty were selected (18 men and 14 women). They 
fulfilled the following inclusion criteria: a) 18 years of age 
or over; b) indication for elective total hip arthroplasty; c) 
signing of consent statement. Their indications were for 
the following reasons: 22 (68.75%) due to osteoarthrosis; 
four (12.5%) due to avascular necrosis of the femoral head; 
four (12.5%) due to sequelae from a proximal femoral 
fracture; and two (6.25%) due to sequelae from congenital 
luxation of the hip. The exclusion criteria were: a) schedul-
ing for elective bilateral hip prosthesis surgery; b) active 
bleeding or high risk of bleeding, thereby contraindicating 
treatment with low molecular weight heparin; c) contrain-
dications regarding the drug to be used or conditions that 
would prevent treatment with anticoagulants; d) conditions 
that would contraindicate bilateral phlebography; e) preg-
nancy or lactation; f) among women of fertile age, nonuse 
of adequate contraceptive methods; g) drug or alcohol 
addiction; h) concomitant use of protease inhibitors for 
HIV treatment; i) undergoing therapy using another study 
product within the 30-day period preceding the start of the 
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current clinical investigation; j) use of intermittent pneu-
matic compression during the period of active treatment; 
k) concomitant participation in another clinical investiga-
tion or study; l) therapy using another type of anticoagu-
lant that could not be interrupted, or another non-permitted 
medication; and m) significant liver disease.
The patients’ mean age was 60 years (± 14.6). The 
youngest patient was 20 years old and the oldest was 82 
years old. None of the patients presented previous liver 
disease, and none of them were using medications that 
would alter liver function tests.
The patients followed a uniform hospital admission 
protocol on the day prior to surgery, with preopera-
tive clinical and laboratory evaluations in accordance 
with medical indications. Samples were taken for the 
following liver enzyme assays: aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), gamma-
glutamyl transpeptidase (GGT), alkaline phosphatase 
(ALP), lactate dehydrogenase (LDH), total bilirubin 
(TB) and direct bilirubin (DB).
Use of enoxaparin was started 12 hours before the 
surgery, with a dose of 40 mg subcutaneously, once a 
day. This was maintained for 35 days. Serial assays 
were performed on the liver function markers: after 
the surgery and on the 6th, 13th, 36th and 65th days after 
the operation.
The following reference values were used: AST 0-41 
U/l, ALT 0-45 U/l, GGT 2-65 U/l, ALP 30-125 U/l, 
LDH 100-220 U/l, TB 0.1-1.2 mg/dl and DB 0-0.4 mg/
dl, as established by the Clinical Reference Laboratory, 
8433 Quivira Road, Lenexa, Kansas, USA, where the 
patients’ samples were analyzed.
RESULTS
In four patients (13%), one or more enzymes present 
elevated preoperative values (ALT and GGT). These 
cases were excluded from the study. During the immedi-
ate postoperative period, three patients (9%) presented 
elevated AST levels, two (6%) ALT, three (9%) GGT 
and ten (31%) LDH, i.e. a total of 13 patients (41%) 
with abnormalities. On the 6th day after the operation, 
six (19%) presented elevated AST, three (9%) ALT, 12 
(38%) GGT, three (9%) ALP and five (16%) LDH, i.e. 
a total of 15 patients (47%) with abnormalities. On the 
13th day, two (6%) presented elevated AST, four (13%) 
ALT, twelve (38%) GGT, five (9%) ALP and seventeen 
(53%) LDH, i.e. a total of 24 patients (75%) with abnor-
malities. On the 36th day, two (6%) presented elevated 
AST, one (3%) ALT, four (13%) GGT, one (3%) ALP 
and seven (22%) LDH, i.e. a total of 10 patients (31%) 
with abnormalities. On the 65th day, one patient (3%) 
presented elevated ALT (9%), five (16%) GGT, three 
(9%) ALP and none with abnormal LDH, i.e. a total of 
eight patients (25%) with abnormalities (Table 1).
Table 1 – Elevated liver enzymes
Enzyme Day 0 Day 1 Day 6 Day 13 Day 36 Day 65
AST 0 3 (9%) 6 (19%) 2 (6%) 2 (6%) 1 (3%)
ALT 3 (9%) 2 (6%) 3 (9%) 4 (13%) 1 (3%) 3 (9%)
GGT 3 (9%) 3 (9%) 12 (38%) 12 (38%) 4 (13%) 5 (16%)
ALP 0 0 3 (9%) 3 (9%) 1 (3%) 3 (9%)
LDH 0 10 (31%) 5 (16%) 17 (53%) 7 (22%) 0
Total 4 (13%)* 13 (41%) 15 (47%) 24 (75%) 10 (31%) 8 (25%)
AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl trans-
peptidase; ALP: alkaline phosphatase; LDH: lactate dehydrogenase
* Patients excluded from the study
The analysis on bilirubins did not demonstrate any 
abnormalities in any of the patients, either before the 
operation or during the 65 days of follow-up. None of 
the patients presented any signs or symptoms relating 
to liver function abnormalities (Figure 1).
AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl trans-
peptidase; ALP: alkaline phosphatase; LDH: lactate dehydrogenase
Figure 1 – Mean curve for liver enzymes
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DISCUSSION
It is known that non-fractionated heparin presents a 
relationship with asymptomatic elevation of transami-
nases. There is no correlation between such abnormali-
ties and clinical evidence of hepatic lesions. In published 
reports in the literature, liver enzyme values have be-
come normalized after suspension of treatment with non-
fractionated heparin(7).
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The recently created selective inhibitors of factor Xa, 
which are still at the clinical study phase, have been found 
to present significant dose-dependent abnormalities in 
transaminase values during the treatment, without evident 
clinical abnormalities. The values become normalized after 
suspension of the treatment(7-9).
In our study, we found abnormalities in the liver 
function tests on most of the patients treated with enox-
aparin, reaching 75% of them on the 13th day after the 
operation. In addition to the transaminases, there were 
elevated values for the enzymes GGT, ALP and LDH. 
The behavior of these abnormalities corresponded to 
what can be seen in the literature(3,6-8), with elevation 
right at the start of the treatment, a peak occurring after 
around two weeks of medication use, and normalization 
after 60 days.
The values for total and direct bilirubin remained 
within the limits of normality throughout the study. We 
did not find any reports in the literature in relation to 
abnormalities of bilirubin metabolism among patients 
using enoxaparin.
Despite the abnormalities found in this study, none of 
the patients presented clinical signs or symptoms relating 
to the elevation of liver enzyme levels. These abnor-
malities showed a tendency towards normalization after 
suspension of the treatment, with a gradual decline in the 
values during the follow-up.
These data resemble what can be seen in the 
literature(3,6-8), and it was not possible to correlate any un-
favorable outcome with the elevations in the liver function 
tests among these patients who underwent total hip arthro-
plasty using enoxaparin as prophylaxis against DVT.
CONCLUSION
Most of the patients who used enoxaparin as pro-
phylaxis against DVT/PTE presented abnormalities in 
laboratory tests on liver function, without clinical reper-
cussions. These abnormalities became normalized with 
suspension of the treatment.
The greatest abnormality was in relation to LDH, 
which presented elevated values in 53% of the cases on 
the 13th day of enoxaparin administration.
